A Tale Of Two Targeted Therapies
This article was originally published in RPM Report
Executive Summary
FDA’s oncology office director suggests Ariad’s ponatinib and ChemGenex’s Omapro represent the best and worst of times, respectively, in the quality of development programs for personalized medicines.